ARTICLE: Long-term Follow-up of Hepatitis C Patients Who Achieved Sustained Virologic Response in the Pragmatic PRIORITIZE Study
AUTHORS: Anna S Lok, Juhi Moon, Kenneth E Sherman, Mandana Khalili, Dawn Fishbein, K Rajender Reddy; PRIORITIZE Study Team (Giuseppe Morelli, Joy Peter, David R Nelson, Brian Pearlman, Larry Michael, Michael W Fried, Jodi B Segal, Mark S Sulkowski)
JOURNAL: Clin Gastroenterol Hepatol. 2023 Feb;21(2):546-548.e4. doi: 10.1016/j.cgh.2022.01.059. Epub 2022 Feb 17.
Abstract
Multiple real-world studies have confirmed the safety and efficacy of hepatitis C (HCV) direct-acting antivirals (DAAs); however, few studies have provided data on long-term outcomes of patients without cirrhosis after achieving sustained virologic response (SVR).1-3 The aims of this analysis were to describe, among individuals in the PRIORITIZE Study achieving SVR: (1) the frequency of laboratory testing and imaging during long-term follow-up (LTFU), (2) changes in liver tests, (3) occurrence of hepatic decompensation or hepatocellular carcinoma (HCC) and deaths, and (4) durability of SVR.
For the full article, click here.
For a link to the abstract, click here.
